Seeking Alpha

AstraZeneca (AZN +0.2%) says an Appeals Court has upheld the decision finding that the substance...

AstraZeneca (AZN +0.2%) says an Appeals Court has upheld the decision finding that the substance patent protecting Crestor is valid and enforceable. The defendants may seek a rehearing or review by the U.S. Supreme Court. Absent a reversal, none of the Abbreviated New Drug Applications filed may be approved by the FDA prior to expiration of the patent, which expires in 2016. The ruling covers rosuvastatin calcium, the active ingredient in Crestor.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|